首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   179073篇
  免费   16582篇
  国内免费   9603篇
耳鼻咽喉   1713篇
儿科学   3108篇
妇产科学   3167篇
基础医学   16517篇
口腔科学   3704篇
临床医学   22227篇
内科学   24162篇
皮肤病学   2062篇
神经病学   7342篇
特种医学   5934篇
外国民族医学   40篇
外科学   18161篇
综合类   34197篇
现状与发展   29篇
一般理论   18篇
预防医学   15063篇
眼科学   4058篇
药学   19645篇
  191篇
中国医学   11710篇
肿瘤学   12210篇
  2024年   458篇
  2023年   2180篇
  2022年   4803篇
  2021年   7421篇
  2020年   5730篇
  2019年   4531篇
  2018年   4963篇
  2017年   5146篇
  2016年   4342篇
  2015年   7172篇
  2014年   9288篇
  2013年   10115篇
  2012年   14728篇
  2011年   15884篇
  2010年   12239篇
  2009年   10568篇
  2008年   12216篇
  2007年   11757篇
  2006年   11002篇
  2005年   9636篇
  2004年   6860篇
  2003年   5998篇
  2002年   4855篇
  2001年   4240篇
  2000年   3696篇
  1999年   2979篇
  1998年   1373篇
  1997年   1277篇
  1996年   1065篇
  1995年   984篇
  1994年   940篇
  1993年   521篇
  1992年   911篇
  1991年   813篇
  1990年   680篇
  1989年   586篇
  1988年   531篇
  1987年   452篇
  1986年   379篇
  1985年   296篇
  1984年   189篇
  1983年   174篇
  1982年   98篇
  1981年   94篇
  1979年   142篇
  1978年   111篇
  1977年   83篇
  1974年   94篇
  1973年   72篇
  1972年   87篇
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
1.
2.
背景 医患沟通障碍是导致医疗纠纷发生的主要原因之一。目前,我国对医务人员医患沟通能力的评价研究较少,缺乏信效度良好的评估工具。 目的 构建"五习惯"医患沟通评价量表(5HCS),检验其信度和效度。 方法 2014年3月,采用Brislin翻译法在"四习惯"医患沟通评价体系(4HCS)的基础上,形成5HCS初稿;2014年4—6月,采用德尔菲法,使用问卷分两轮征求专家意见,根据专家意见修订条目后形成5HCS定稿;2018年3月,使用新构建的5HCS对127名住院医师的医患沟通能力进行评估,通过分析其评价数据,检验量表的内部一致性、评价者间信度、内容效度和标准关联效度。 结果 正式版5HCS包含5个维度("尊重示善,融洽关系""采集信息,引导观点""表达共情,建立信任""风险告知,知情同意""提供诊断,协商决策"),21个条目。量表的Cronbach's α系数为0.716,各维度与量表总分的r值为0.524~0.692,各条目的内容效度指数(I-CVI)≥0.81,量表总分的评价者间信度r值为0.912,组内相关系数(ICC)=0.912,标准关联效度以中文版医患沟通技能评价量表(SEGUE)为标准,两个量表总分之间的r值为0.377(P<0.01)。 结论 5HCS具有良好的信度和效度,可将其作为我国住院医师医患沟通能力测评工具加以推广应用。  相似文献   
3.
4.
Zedoary tumeric (Curcumae Rhizoma, Ezhu in Chinese) has a long history of application and has great potential in the treatment of liver cancer. The anti liver cancer effect of zedoary tumeric depends on the combined action of multiple pharmacodynamic substances. In order to clarify the specific mechanism of zedoary tumeric against liver cancer, this paper first analyzes the mechanism of its single pharmacodynamic substance against liver cancer, and then verifies the joint anti liver cancer mechanism of its "pharmacodynamic group". By searching the research on the anti hepatoma effect of active components of zedoary tumeric in recent years, we found that pharmacodynamic substances, including curcumol, zedoarondiol, curcumenol, curzerenone, curdione, curcumin, germacrone, β-elemene, can act on multi-target and multi-channel to play an anti hepatoma role. For example, curcumin can regulate miR, GLO1, CD133, VEGF, YAP, LIN28B, GPR81, HCAR-1, P53 and PI3K/Akt/mTOR, HSP70/TLR4 and NF-κB. Wnt/TGF/EMT, Nrf2/Keap1, JAK/STAT and other pathways play an anti hepatoma role. Network pharmacological analysis showed that the core targets of the "pharmacodynamic group" for anti-life cancer are AKT1, EGFR, MAPK8, etc, and the core pathways are neuroactive live receiver interaction, nitrogen metabolism, HIF-1 signaling pathway, etc. At the same time, by comparing and analyzing the relationship between the specific mechanisms of pharmacodynamic substance and "pharmacodynamic group", it is found that they have great reference significance in target, pathway, biological function, determination of core pharmacodynamic components, formation of core target protein interaction, in-depth research of single pharmacodynamic substance, increasing curative effect and so on. By analyzing the internal mechanism of zedoary tumeric pharmacodynamic substance and "pharmacodynamic group" in the treatment of liver cancer, this paper intends to provide some ideas and references for the deeper pharmacological research of zedoary tumeric and the relationship between pharmacodynamic substance and "pharmacodynamic group".  相似文献   
5.
6.
Lessons Learned
  • SCB01A is a novel microtubule inhibitor with vascular disrupting activity.
  • This first‐in‐human study demonstrated SCB01A safety, pharmacokinetics, and preliminary antitumor activity.
  • SCB01A is safe and well tolerated in patients with advanced solid malignancies with manageable neurotoxicity.
BackgroundSCB01A, a novel microtubule inhibitor, has vascular disrupting activity.MethodsIn this phase I dose‐escalation and extension study, patients with advanced solid tumors were administered intravenous SCB01A infusions for 3 hours once every 21 days. Rapid titration and a 3 + 3 design escalated the dose from 2 mg/m2 to the maximum tolerated dose (MTD) based on dose‐limiting toxicity (DLT). SCB01A‐induced cellular neurotoxicity was evaluated in dorsal root ganglion cells. The primary endpoint was MTD. Safety, pharmacokinetics (PK), and tumor response were secondary endpoints.ResultsTreatment‐related adverse events included anemia, nausea, vomiting, fatigue, fever, and peripheral sensorimotor neuropathy. DLTs included grade 4 elevated creatine phosphokinase (CPK) in the 4 mg/m2 cohort; grade 3 gastric hemorrhage in the 6.5 mg/m2 cohort; grade 2 thromboembolic event in the 24 mg/m2 cohort; and grade 3 peripheral sensorimotor neuropathy, grade 3 elevated aspartate aminotransferase, and grade 3 hypertension in the 32 mg/m2 cohort. The MTD was 24 mg/m2, and average half‐life was ~2.5 hours. The area under the curve‐dose response relationship was linear. Nineteen subjects were stable after two cycles. The longest treatment lasted 24 cycles. SCB01A‐induced neurotoxicity was reversible in vitro.ConclusionThe MTD of SCB01A was 24 mg/m2 every 21 days; it is safe and tolerable in patients with solid tumors.  相似文献   
7.
BackgroundComminuted patellar fractures are not rare, and the ideal treatment method remains controversial. The present study was conducted to evaluate effects and compare complications of two different methods used to treat comminuted patellar fractures.MethodsFrom March 2010 to August 2016, 102 cases of 34-C2 or 34-C3 comminuted patellar fractures were treated at our hospital, wherein patients received two different treatments: titanium cable tension band with cerclage method (group A) and intrafragmentary screws with X-shaped plating technique (group B). At follow-ups, articular step-off, range of motion (ROM), Lysholm scores, time of union, and complications were recorded and analyzed. Radiographic and clinical data as well as rate of complications were statistically analyzed.ResultsIn total, 87 patients were included in the final analysis (n = 47 in group A and n = 40 in group B). No significant differences were noted in terms of cost of implant, age, gender, rate of 34-C3 fractures, rate of layered inferior pole fractures, postoperative articular step-off and union time. At 2-year follow-up, average Lysholm scores, ROM and rate of complications were (89.0 ± 4.5), (122°±12°) and (27.7%) in group A and (90.2 ± 3.9), (124°±11°) and (17.5%) in group B, respectively, with no significant differences (p > 0.05). The mean time of surgery in group B was shorter than that in group A with significant difference (p < 0.05).ConclusionsTreatment using the intrafragmentary screws and plate method for amenable comminuted patellar fractures achieved similar complication rate and favorable functional outcomes at the 2-year follow-up, which was comparable to the titanium cable tension band with cerclage method. Thus, the intrafragmentary screws and plate method is effective, safe and convenient for 34-C2/C3 comminuted patellar fractures, especially appropriate for patients with layered fragments.  相似文献   
8.
目的:探讨环状RNA hsa_circ_0006867在结直肠癌中的表达及其与临床病理因素的关系。方法:全转录组测序筛选结直肠癌中特异circRNAs表达谱,挑选出差异表达显著的hsa_circ_0006867,qRT-PCR检测54例结直肠癌组织及癌旁组织中hsa_circ_0006867表达情况,分析其表达水平与结直肠癌临床病理特征的相关性,ROC曲线分析hsa_circ_0006867在结直肠癌中的诊断价值。结果:测序获得circRNAs在结直肠癌中的差异表达谱,qRT-PCR验证hsa_circ_0006867在结直肠癌中表达下调(P<0.05)。其表达水平与肿瘤分化程度和远处转移有关(P<0.05)。ROC曲线显示hsa_circ_0006867诊断结直肠癌AUC为0.851(95%CI:0.775~0.927),当截断值为0.0146时,敏感度为88.46%(95%CI:0.770~0.946),特异度为73.08%(95%CI:0.598~0.832),差异具有统计学意义(P<0.001)。结论:hsa_circ_0006867在结直肠癌中表达下调,与相关临床病理特征密切联系,可作为潜在结直肠癌临床诊断指标。  相似文献   
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号